In this warm season, we ushered in the fiery May. On May 28, 2022, the "Cloud Forum on New Ideas for Diagnosis and Treatment of Myelosuppression and Typical Cases of Observation of the Efficacy of Shengbai Oral Liquid (Mixture) in the Prevention and Treatment of Leukopenia after Chemotherapy" hosted by Hubei Mengyang Pharmaceutical Co., Ltd. was held in the cloud.

The conference was opened by Professor Sun Tao from the East Hospital of Beijing University of Chinese Medicine, the chairman of the conference. Professor Sun Tao showed that China has the largest population of cancer patients in the world, which is characterized by high morbidity, high mortality and heavy disease burden. In order to reduce the incidence of toxicity and side effects related to tumor treatment and strengthen the comprehensive tumor treatment system, the project interpretation and typical case sharing meeting of "Observation and Case Collection of Efficacy of Shengbai Oral Liquid (Mixture) in the Prevention and Treatment of Leukopenia after Chemotherapy" named by the China Association of Traditional Chinese Medicine was held in the cloud today. At the same time, it is expected that in the future, with the development of the "Observation and Case Collection Project of the Efficacy of Shengbai Oral Liquid (Mixture) in the Prevention and Treatment of Leukopenia after Chemotherapy", the overall improvement of the level of cancer treatment can be promoted.

At the conference, Professor Gao Hong from the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine interpreted the "Observation Case Collection Project of the Efficacy of Shengbai Oral Liquid (Mixture) in the Prevention and Treatment of Leukopenia after Chemotherapy". It was expounded from three aspects: project basis, scheme interpretation and practical operation. She also systematically introduced the significant advantages of Shengbai Oral Liquid (Mixture) in the treatment of leukopenia, and mentioned that more mechanism and clinical studies are being carried out on Shengbai Oral Liquid (Mixture) in order to actively play a role in anti-tumor therapy. At the same time, it also emphasized that the actual operation of the "Observation Case Collection Project of Shengbai Oral Liquid (Mixture) for the Prevention and Treatment of Leukopenia after Chemotherapy" is relatively simple, and it is hoped that more experts will join it to witness the clinical value of Shengbai Oral Liquid (Mixture).

In the case sharing session, Dr. Sun Xiaojing from the East Hospital of Beijing University of Chinese Medicine and Director Pan Lin from the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine jointly explained the typical effective cases of myelosuppression caused by chemotherapy caused by Shengbai Oral Liquid (Mixture), and summarized that the efficacy of Shengbai Oral Liquid (Mixture) in the prevention and treatment of myelosuppression caused by chemotherapy in cancer patients is accurate and can be evaluated by quantitative indicators. Based on clinical practice experience, Director Pan Lin pointed out that Shengbai Oral Liquid (Mixture) has significant efficacy in improving patients' cancer-related fatigue, especially dizziness, fatigue and other symptoms, and believes that in the near future, there will be more powerful research data to guide clinical practice to bring greater benefits to patients.

Professor Gao Hong, Director Pan Lin of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, and Dr. Sun Xiaojing of the East Hospital of Beijing University of Chinese Medicine discussed the common problems in the operation of the project, and provided practical and good ideas for more experts involved in the project with their valuable experience. At the same time, Professor Gao Hong showed that in the process of project implementation, patient puzzle solving, psychological comfort and related treatment play an equally important role, and patient education is a necessary condition to promote the smooth progress of the "Shengbai Oral Liquid (Mixture) Prevention and Treatment of Leukopenia Efficacy Observation Case Collection Project" after chemotherapy.

Finally, the chairman of the conference, Professor Sun Tao from Beijing University of Chinese Medicine East Hospital, summarized the meeting and expressed his heartfelt thanks and blessings to the enterprises, speakers and participating experts. So far, the meeting has come to a successful conclusion, and everyone has gained a lot, and the meaning is still unfinished. We look forward to meeting offline in the future and enjoying the academic feast!